Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid Marie Holst Olsen, Jens B Sørensen, Birgitte Federspiel, Andreas Kjaer, Carsten P Hansen, Ulrich Knigge, Seppo W Langer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

69 Citationer (Scopus)

Abstract

Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.
OriginalsprogEngelsk
TidsskriftScientific World Journal
Vol/bind2012
Sider (fra-til)170496
Antal sider4
ISSN2356-6140
DOI
StatusUdgivet - 2012

Citationsformater